February 19, 2025 Advancing Neonatal Drug Development Through Collaboration At C-Path’s INC, we believe that meaningful progress in neonatal drug development...
February 18, 2025 C-Path’s CPA-1 Consortium Welcomes Newest Members Kamada, Sanofi Critical Path for Alpha-1 (CPA-1) consortium today announced the addition of biopharmaceutical companies, Kamada...
February 20, 2025 Vivli and RDCA-DAP Present: Data Platform Partnerships to Promote Rare Disease Data Sharing Join Julie Wood, Chief Operating Officer at Vivli, for an engaging webinar, Thursday, February 20, where she’ll discuss...
January 21, 2025 Save the Date: CGIC Returns to D.C. this September We are thrilled to invite you to the 2025 Critical Path Institute® (C-Path) Global Impact Conference (CGIC)...
January 17, 2025 FDA Accepts Qualification Plan for Urine Biomarker Panel to Allow Earlier Detection of Response to Drug-Induced Kidney Injury in Clinical Trials The Foundation for the National Institutes of Health (FNIH) and Critical Path Institute® (C-Path)...
December 10, 2024 Biomarkers 101: A Patient’s Perspective on the Importance of Identifying New Biomarkers Biomarkers are emerging as powerful tools in the field of kidney health, playing a crucial role in the diagnosis, monitoring...
November 27, 2024 A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies Duchenne muscular dystrophy (DMD), a rare pediatric disease, presents numerous challenges when designing clinical trials...
October 1, 2024 The AMR Accelerator Calls to Action: European Capacity for Antibiotic R&D Requires Long-term Funding Note: You are reading this information because Critical Path Institute is a partner of both ERA4TB and Unite4TB.
August 22, 2024 C-Path’s TRxA Announces $250,000 Grant for Drug Development Project in Prostate Cancer C-Path proudly announced today a $250,000 grant award to Peter Wipf, Ph.D...
August 13, 2024 C-Path’s TRxA Announces $250,000 Grant for Drug Development Project on Antibiotic-Resistant Gram-Negative Bacteria C-Path) Translational Therapeutics Accelerator (TRxA) announced today that Kenneth Keiler...
